Amgen to buy Micromet for $1.16 billion

Thursday 26 January 2012

Amgen Inc has agreed to pay $1.16 billion in cash to acquire Micromet Inc, a developer of bispecific antibodies. Micromet’s key asset is blinatumomab, an antibody in early clinical development against acute lymphoblastic leukaemia.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States